Fermion and Simcere Enter into Exclusive License and Collaboration Agreement for First SSTR4 Agonist Targeting in China Investing.com

GUANGZHOU, China, January 17, 2025 /PRNewswire/ — Guangzhou Fermion Technology Co., Ltd. and Just fine Pharmaceutical (TADAWUL:) Group Limited (HKEX: 2096) announced a collaboration to develop a clinical-grade pain treatment product, FZ002-037, targeting SSTR4.

FZ002-037 is a very fermion-selective SSTR4 small molecule. Preclinical studies show that the drug provides peripheral analgesia without central side effects or addiction risks, which makes it a promising option for patients who need long-term pain control. It is the first domestically developed SSTR4 agonist China and the second in the world to reach the medical level. The drug completed Phase I clinical trials in Chinawith Phase II studies for diabetic peripheral neuropathy to begin soon. Potential uses extend to a variety of chronic and acute pain conditions.

Dr. Deco Deng, Founder of Fermion, said: “We are pleased to partner with Simcere, a leading pharmaceutical company. As the first domestically developed and the world’s second leading SSTR4 agonist to enter the clinical stage, FZ002-037 is Promise By leveraging Simcere’s strong development and commercialization capabilities, we are confident of accelerating its development to provide better treatment options for patients with the problem. . pain.”

Zhou Gaobo, Chief Financial Officer of Simcere, adds: “Pain has a significant impact on patients’ quality of life and remains a major unmet clinical need. Addressing these ‘clinical pain’ has always been Simcere’s core business. We look forward to working with new partners like Fermion to deliver effective and safe medicines to patients as soon as possible.”

Under the agreement, Simcere will receive exclusive rights to develop and commercialize FZ002-037 in Greater China (Mainland China, Hong Kong, Macauand Taiwan). Fermion will receive an upfront payment, milestone payments, and prorated royalties based on future sales.

About Fermion Technology

Fermion is a medical-grade, AI-driven biotech company founded in 2019. The company focuses on developing a variety of advanced (BIC) and early stage (FIC) products in the central nervous system. (CNS) and autoimmune. fields. Using its proprietary Drug Studio AI platform, Fermion prioritizes high-throughput target selection and cell targeting to minimize unintended effects, ensure accurate delivery to target cells, and promote the development of new drugs with improved safety data.

For more information, please visit: www.fulmz.com.

About Simcere Pharmaceutical

Simcere Pharmaceutical Group Limited (2096.HK) is a new R&D driven pharmaceutical company, and has the State Key Laboratory of Neurology and Oncology Drug Development. Simcere aims to “give today’s patients the medicine of the future” in the following primary treatment areas: oncology, central nervous system, autoimmunity and anti-infection. In addition, Simcere is also expanding its presence in disease areas with critical medical needs in the future.

Simcere’s industry-leading operational capabilities and commitment to synergistic development have also enabled various strategic partnerships and are seen as partners of choice by new biopharmaceutical companies, clinical centers and research groups. to. China and the whole world.

For more information, please visit: www.simcere.com

Regarding FZ002-037

FZ002-037 is a Phase II preparation for the treatment of non-opioid pain that acts as an oral SSTR4 agonist. It is the first SSTR4 agonist to enter clinical trials China and second in the world. The drug shows excellent selectivity, with a double-digit pM EC50 and strong efficacy in many types of chronic and acute pain. Phase I studies revealed a good safety profile, with no reported CNS or gastrointestinal adverse events, and a favorable PK profile (once daily). These characteristics highlight its potential as an effective treatment option to address the unmet need for chronic, non-injury pain relief.

For more information, please visit: https://www.fulmz.com

Investor and Media Contact: pr@fulmz.com